Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Revelation Biosciences Inc (REVBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: REVBW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.5% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.09 | 52 Weeks Range 0.00 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.00 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.68% | Return on Equity (TTM) -233.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 941937 |
Shares Outstanding - | Shares Floating 941937 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing immunomodulatory therapies and diagnostics for the prevention and treatment of disease. The company was founded in 2011.
Core Business Areas
- REVTx-99a: A pharmaceutical product for the treatment of allergic rhinitis.
- REVTx-300: An immunomodulatory therapy targeting chronic organ inflammation.
- REVTx-200: A therapeutic targeting lung inflammation
Leadership and Structure
James Rolke is the CEO. The company has a board of directors and a management team overseeing its various operational areas.
Top Products and Market Share
Key Offerings
- REVTx-99a: A nasal spray that is currently in Phase 2 clinical trials for allergic rhinitis. The competitors include allergy medications from major pharmaceutical companies like Sanofi (SNY), GSK (GSK), and Bayer (BAYRY). Revenue for this product is currently 0 as it is still in clinical trials. Market share is also not available yet, as the product has not been launched yet.
- REVTx-300: An intravenous therapy in preclinical development that targets chronic organ inflammation. Competitors are many other companies who have therapeutics in this area, but they have not been publicly defined by Revelation Biosciences. Revenue for this product is currently 0 as it is still in pre-clinical development. Market share is also not available yet, as the product has not been launched yet.
- REVTx-200: A therapeutic targeting lung inflammation in preclinical development. Competitors are many other companies who have therapeutics in this area, but they have not been publicly defined by Revelation Biosciences. Revenue for this product is currently 0 as it is still in pre-clinical development. Market share is also not available yet, as the product has not been launched yet.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The industry is also highly competitive, with numerous companies vying for market share.
Positioning
Revelation Biosciences Inc. is a clinical-stage company focused on immunomodulatory therapies, positioning it in a specific niche within the broader biopharmaceutical industry. Their competitive advantage relies on the novelty and efficacy of their drug candidates.
Total Addressable Market (TAM)
The TAM for allergic rhinitis treatments is estimated to be billions of dollars annually. The TAM for treatments targeting chronic organ inflammation is also estimated to be billions of dollars annually. Revelation Biosciences Inc. aims to capture a portion of these markets with their drug candidates.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory technology platform
- Promising clinical trial results for REVTx-99a
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- FDA fast-track designation for REVTx-99a
Threats
- Competition from established pharmaceutical companies
- Unfavorable regulatory changes
- Failure to secure adequate funding
Competitors and Market Share
Key Competitors
- SNY
- GSK
- BAYRY
Competitive Landscape
Revelation Biosciences Inc. faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its success depends on demonstrating the superior efficacy and safety of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived probability of success for its drug candidates.
Recent Initiatives: Recent initiatives include advancing REVTx-99a through Phase 2 clinical trials and exploring partnerships to expand the development of REVTx-300.
Summary
Revelation Biosciences is a clinical stage company with limited revenue. Its future depends on the successful development of its drug candidates, especially REVTx-99a. It is in a competitive industry with larger players, requiring strategic partnerships and efficient capital allocation to succeed. Investors need to look out for clinical trial results, which will heavily influence the stock price.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where publicly available)
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-16 | Chairman & CEO Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com | ||
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.